RYZODEG 70/30 Drug Profile
✉ Email this page to a colleague
Summary for Tradename: RYZODEG 70/30
| High Confidence Patents: | 9 |
| Applicants: | 1 |
| BLAs: | 1 |
| Recent Clinical Trials: | See clinical trials for RYZODEG 70/30 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for RYZODEG 70/30 |
Recent Clinical Trials for RYZODEG 70/30
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Sunshine Lake Pharma Co., Ltd. | Phase 3 |
| Huashan Hospital | Phase 3 |
| Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
Recent Litigation for RYZODEG 70/30
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Novo Nordisk, Inc. v. Mylan Pharmaceuticals, Inc. | 2022-08-08 |
| In Re: Ozempic (Semaglutide) Patent Litigation | 2022-08-05 |
| IN RE: Ozempic (Semaglutide) Patent Litigation | 2022-05-06 |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for RYZODEG 70/30 Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for RYZODEG 70/30 Derived from Company Disclosures
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc. | RYZODEG 70/30 | insulin degludec and insulin aspart | Injection | 203313 | ⤷ Try a Trial | 2016-06-20 | Company disclosures |
| Novo Nordisk Inc. | RYZODEG 70/30 | insulin degludec and insulin aspart | Injection | 203313 | ⤷ Try a Trial | 2021-01-05 | Company disclosures |
| Novo Nordisk Inc. | RYZODEG 70/30 | insulin degludec and insulin aspart | Injection | 203313 | ⤷ Try a Trial | 2023-08-05 | Company disclosures |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for RYZODEG 70/30 Derived from Patent Text Search
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc. | RYZODEG 70/30 | insulin degludec and insulin aspart | Injection | 203313 | ⤷ Try a Trial | 2031-10-25 | Patent claims search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
International Patents for RYZODEG 70/30
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2531988 | ⤷ Try a Trial |
| Denmark | 2373361 | ⤷ Try a Trial |
| Russian Federation | 2388498 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for RYZODEG 70/30
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C201300035 | Spain | ⤷ Try a Trial | PRODUCT NAME: INSULINA DEGLUDEC; NATIONAL AUTHORISATION NUMBER: EU/1/12/807/001, 004, 005, 007-009, 012, 013, 015; DATE OF AUTHORISATION: 20130121; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/12/807/001, 004, 005, 007-009, 012, 013, 015; DATE OF FIRST AUTHORISATION IN EEA: 20130121 |
| C300596 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: INSULINE DEGLUDEC; REGISTRATION NO/DATE: EU/1/12/807/001EU/1/12/807/004EU/1/12/807/005EU/1/12/807/007EU/1/12/807/008EU/1/12/807/009EU/1/12/807/012EU/1/12/807/013EU/1/12/807/015 2013210121 |
| 1390036-0 | Sweden | ⤷ Try a Trial | PRODUCT NAME: KOMBINATION AV INSULIN DEGLUDEK OCH INSULIN ASPART; REG. NO/DATE: EU/1/12/806/001 20130121 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
